Read by QxMD icon Read


Jean-Pierre Pelletier, Jean-Pierre Raynauld, François Abram, Marc Dorais, Philippe Delorme, Johanne Martel-Pelletier
BACKGROUND: The weight of recommendation for intra-articular therapies such as hyaluronic acid injections varies from one set of guidelines to another, and they have not yet reached unanimity with respect to the usefulness of intra-articular hyaluronic acid (IAHA) injections for the symptomatic treatment of knee osteoarthritis (OA). Among the reasons for the controversy is that the current literature provides inconsistent results and conclusions about such treatment. This study aimed at identifying determinants associated with a better response to IAHA treatment in knee OA...
March 1, 2018: Arthritis Research & Therapy
Mohit Bhandari, Raveendhara R Bannuru, Eric M Babins, Johanne Martel-Pelletier, Moin Khan, Jean-Pierre Raynauld, Renata Frankovich, Deanna Mcleod, Tahira Devji, Mark Phillips, Emil H Schemitsch, Jean-Pierre Pelletier
Osteoarthritis (OA) is a chronic condition characterized by a loss of joint cartilage and is a major cause of disability in Canada, with an estimated CN$195 billion annual cost. Knee OA leads to persistent pain and loss of function, and treatment goals primarily focus on symptom relief and retention of function. Intra-articular hyaluronic acid (IAHA) has therapeutic benefits, and numerous recently published meta-analyses (MAs) and commentaries have highlighted new evidence on the role of IAHA therapy for knee OA...
September 2017: Therapeutic Advances in Musculoskeletal Disease
Johanne Martel-Pelletier, Jean-Pierre Raynauld, François Mineau, François Abram, Patrice Paiement, Philippe Delorme, Jean-Pierre Pelletier
BACKGROUND: There is an obvious need to identify biomarkers that could predict patient response to an osteoarthritis (OA) treatment. This post hoc study explored in a 2-year randomized controlled trial in patients with knee OA, the likelihood of some serum biomarkers to be associated with a better response to chondroitin sulfate in reducing cartilage volume loss. METHODS: Eight biomarkers were studied: hyaluronic acid (HA), C reactive protein (CRP), adipsin, leptin, N-terminal propeptide of collagen IIα (PIIANP), C-terminal crosslinked telopeptide of type I collagen (CTX-1), matrix metalloproteinase-1 (MMP-1), and MMP-3...
July 20, 2017: Arthritis Research & Therapy
Jean-Luc Senécal, Jean-Pierre Raynauld, Yves Troyanov
No abstract text is available yet for this article.
May 2017: Arthritis & Rheumatology
Jean-Pierre Raynauld, Jean-Pierre Pelletier, Philippe Delorme, Pierre Dodin, François Abram, Johanne Martel-Pelletier
Objectives: Knee bone curvature assessed by MRI was associated with OA cartilage loss. A recent knee OA trial demonstrated the superiority of chondroitin sulfate over celecoxib (comparator) at reducing cartilage volume loss (CVL) in the medial compartment (condyle). The main objectives were to identify which baseline bone curvature regions of interest (BCROI) best associated with CVL and investigate whether baseline BCROI and 2-year change are correlated with the protective effect of chondroitin sulphate on CVL...
June 1, 2017: Rheumatology
A Senay, J Delisle, J Raynauld, A Banica, Y Troyanov, P Beaumont, M Giroux, A Jodoin, Y Laflamme, S Leduc, J MacThiong, M Malo, G Maurais, H Nguyen, S Parent, P Ranger, D Rouleau, S Perreault, J C Fernandes
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Jean-Pierre Pelletier, Jean-Pierre Raynauld, André D Beaulieu, Louis Bessette, Frédéric Morin, Artur J de Brum-Fernandes, Philippe Delorme, Marc Dorais, Patrice Paiement, François Abram, Johanne Martel-Pelletier
BACKGROUND: In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in a number of studies using radiography to have a structure-modifying effect, to date CS use is still under debate. A clinical study using quantitative magnetic resonance imaging (qMRI) is therefore of the utmost importance. Here we report data from a 24-month, randomised, double-blind, double-dummy, controlled, comparative exploratory study of knee OA. The primary endpoint was to determine the effect of CS 1200 mg/day versus celecoxib 200 mg/day on cartilage volume loss (CVL) in the lateral compartment over time as measured by qMRI...
November 3, 2016: Arthritis Research & Therapy
Jean-Pierre Raynauld, Jean-Pierre Pelletier, François Abram, Pierre Dodin, Philippe Delorme, Johanne Martel-Pelletier
OBJECTIVE: To examine the long-term (6-year) effect of combined glucosamine (Glu) and chondroitin sulfate (CS) treatment on cartilage volume in knee osteoarthritis (OA). METHODS: Participants were from the Osteoarthritis Initiative progression and incidence subcohorts, had magnetic resonance imaging (MRI) of the target knee at baseline and 6 years, joint space width >1 mm, and data available on Glu/CS consumption (n = 1,593). They were stratified into 2 main groups based on whether or not they had medial meniscal extrusion at baseline...
October 2016: Arthritis Care & Research
Johanne Martel-Pelletier, Jean-Pierre Raynauld, Marc Dorais, François Abram, Jean-Pierre Pelletier
OBJECTIVE: Limited studies have explored the association between adipokines and knee OA structural progression using quantitative MRI (qMRI), and very few have included total knee replacement (TKR) as a disease outcome. The objective of this study was to compare serum levels of five adipokines to cartilage volume loss (CVL) and investigate their predictive value for TKR. METHODS: The according-to-protocol population (n = 138) of a knee OA trial was used. Serum levels of adipsin (complement factor D), leptin, adiponectin, resistin and serpin E1, and cartilage volume were determined at baseline and 24 months with specific ELISAs and qMRI, respectively...
April 2016: Rheumatology
A Senay, J Delisle, J P Raynauld, S N Morin, J C Fernandes
UNLABELLED: We determined if nurses can manage osteoporotic fractures in a fracture liaison service by asking a rheumatologist and an internist to assess their clinical decisions. Experts agreed on more than 94 % of all nurses' actions for 525 fragility fracture patients, showing that their management is efficient and safe. INTRODUCTION: A major care gap exists in the investigation of bone fragility and initiation of treatment for individuals who have sustained a fragility fracture...
April 2016: Osteoporosis International
Camille Roubille, Johanne Martel-Pelletier, François Abram, Marc Dorais, Philippe Delorme, Jean-Pierre Raynauld, Jean-Pierre Pelletier
OBJECTIVE: In the perspective of personalized management of osteoarthritis (OA), a clinically relevant concern is the impact of meniscal extrusion (Ext) on response to treatment. This study aimed at determining the effects of conventional OA pharmacological treatments and those of the combination of glucosamine and chondroitin sulfate (Glu/CS) on knee structural changes in the presence or absence of Ext, using data from the progression cohort of the Osteoarthritis Initiative. METHODS: In this longitudinal study, knee OA participants were stratified based on whether (+) or not (-) they received analgesics/NSAIDs (+ and -analgesics/NSAIDs) and/or Glu/CS (+ and -Glu/CS) for 24 consecutive months and on the presence (Ext+) or absence (Ext-) of medial meniscal extrusion at baseline...
December 2015: Seminars in Arthritis and Rheumatism
D J Hunter, R D Altman, F Cicuttini, M D Crema, J Duryea, F Eckstein, A Guermazi, R Kijowski, T M Link, J Martel-Pelletier, C G Miller, T J Mosher, R E Ochoa-Albíztegui, J-P Pelletier, C Peterfy, J-P Raynauld, F W Roemer, S M Totterman, G E Gold
Significant advances have occurred in our understanding of the pathogenesis of knee osteoarthritis (OA) and some recent trials have demonstrated the potential for modification of the disease course. The purpose of this expert opinion, consensus driven exercise is to provide detail on how one might use and apply knee imaging in knee OA trials. It includes information on acquisition methods/techniques (including guidance on positioning for radiography, sequence/protocol recommendations/hardware for magnetic resonance imaging (MRI)); commonly encountered problems (including positioning, hardware and coil failures, sequences artifacts); quality assurance (QA)/control procedures; measurement methods; measurement performance (reliability, responsiveness, validity); recommendations for trials; and research recommendations...
May 2015: Osteoarthritis and Cartilage
Camille Roubille, Johanne Martel-Pelletier, Jean-Pierre Raynauld, François Abram, Marc Dorais, Philippe Delorme, Jean-Pierre Pelletier
INTRODUCTION: To evaluate the impact of meniscal extrusion (Ext) on knee osteoarthritis (OA) structural progression and on response to strontium ranelate (SrRan) treatment at 36 months in patients with (+) or without (-) Ext, in association (+) or not (-) with bone marrow lesions (BML) in the medial compartment using X-rays (JSW) and qMRI. METHODS: Patients from the qMRI substudy of the SEKOIA trial (SrRan 1 g/day, n = 113; SrRan 2 g/day, n = 105; placebo, n = 112) were stratified based on whether meniscal extrusion and/or BML were present or not in the medial compartment...
2015: Arthritis Research & Therapy
Jean-Pierre Raynauld, Jean-Pierre Pelletier, Camille Roubille, Marc Dorais, François Abram, Wei Li, Yuanyuan Wang, Jessica Fairley, Flavia M Cicuttini, Johanne Martel-Pelletier
OBJECTIVE: Studies have proposed vastus medialis (VM) muscle cross-sectional area change as a variable associated with cartilage volume loss in knee osteoarthritis (OA). However, the VM also includes fat (%Fat), which may influence knee function. This study analyzed the VM area and %Fat data, separately and in combination, to predict symptoms, cartilage volume loss, and bone marrow lesion (BML) change in knee OA. METHODS: This study included the according-to-protocol population (n = 143) of a 2-year knee OA randomized clinical trial having magnetic resonance imaging at baseline and 2 years...
October 2015: Arthritis Care & Research
James Khan, Joel Katz, Janice Montbriand, Salima Ladak, Stuart McCluskey, Coimbatore Srinivas, Raynauld Ko, David Grant, Ashleene Bradbury, Yannick LeManach, Hance Clarke
Living donor liver resections are associated with significant postoperative pain. Epidural analgesia is the gold standard for postoperative pain management, although it is often refused or contraindicated. Surgically placed abdominal wall catheters (AWCs) are a novel pain modality that can potentially provide pain relief for those patients who are unable to receive an epidural. A retrospective review was performed at a single center. Patients were categorized according to their postoperative pain modality: intravenous (IV) patient-controlled analgesia (PCA), AWCs with IV PCA, or patient-controlled epidural analgesia (PCEA)...
April 2015: Liver Transplantation
Jean-Luc Senécal, Catherine Isabelle, Marvin J Fritzler, Ira N Targoff, Rose Goldstein, Michel Gagné, Jean-Pierre Raynauld, France Joyal, Yves Troyanov, Marie-Christine Dabauvalle
Autoimmune myositis encompasses various myositis-overlap syndromes, each being identified by the presence of serum marker autoantibodies. We describe a novel myositis-overlap syndrome in 4 patients characterized by the presence of a unique immunologic marker, autoantibodies to nuclear pore complexes. The clinical phenotype was characterized by prominent myositis in association with erosive, anti-CCP, and rheumatoid factor-positive arthritis, trigeminal neuralgia, mild interstitial lung disease, Raynaud phenomenon, and weight loss...
November 2014: Medicine (Baltimore)
Yves Troyanov, Ira N Targoff, Marie-Pier Payette, Jean-Pierre Raynauld, Suzanne Chartier, Jean-Richard Goulet, Josiane Bourré-Tessier, Eric Rich, Tamara Grodzicky, Marvin J Fritzler, France Joyal, Martial Koenig, Jean-Luc Senécal
Dermatomyositis (DM) is a major clinical subset of autoimmune myositis (AIM). The characteristic DM rash (Gottron papules, heliotrope rash) and perifascicular atrophy at skeletal muscle biopsy are regarded as specific features for this diagnosis. However, new concepts are challenging the current definition of DM. A modified Bohan and Peter classification of AIM was proposed in which the core concept was the inclusion of the diagnostic significance of overlap connective tissue disease features. In this clinical classification, a DM rash in association with myositis in the absence of overlap features indicates a diagnosis of pure DM...
November 2014: Medicine (Baltimore)
Camille Roubille, Jean-Pierre Raynauld, François Abram, Patrice Paiement, Marc Dorais, Philippe Delorme, Louis Bessette, André D Beaulieu, Johanne Martel-Pelletier, Jean-Pierre Pelletier
INTRODUCTION: Pain in osteoarthritis (OA) has been classically attributed to joint structural damage. Disparity between the degree of radiographic structural damage and the severity of symptoms implies that factors other than the joint pathology itself contribute to the pain. Peripheral and central sensitization have been suggested as two of the underlying mechanisms that contribute to pain in OA. The aim of this study was to explore in symptomatic knee OA patients, the structural changes assessed by magnetic resonance imaging (MRI) that could be used as markers of neuropathic pain (NP)...
December 14, 2014: Arthritis Research & Therapy
Paul Karanicolas, Sean Cleary, Paul McHardy, Stuart McCluskey, Jason Sawyer, Salima Ladak, Calvin Law, Alice Wei, Natalie Coburn, Raynauld Ko, Joel Katz, Alex Kiss, James Khan, Srinivas Coimbatore, Jenny Lam-McCulloch, Hance Clarke
BACKGROUND: The current standard for pain control following liver surgery is intravenous, patient-controlled analgesia (IV PCA) or epidural analgesia. We have developed a modification of a regional technique called medial open transversus abdominis plane (MOTAP) catheter analgesia. The MOTAP technique involves surgically placed catheters through the open surgical site into a plane between the internal oblique muscle and the transverse abdominis muscle superiorly. The objective of this trial is to assess the efficacy of this technique...
June 21, 2014: Trials
M Lotz, J Martel-Pelletier, C Christiansen, M-L Brandi, O Bruyère, R Chapurlat, J Collette, C Cooper, G Giacovelli, J A Kanis, M A Karsdal, V Kraus, W F Lems, I Meulenbelt, J-P Pelletier, J-P Raynauld, S Reiter-Niesert, R Rizzoli, L J Sandell, W E Van Spil, J-Y Reginster
Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint remodelling and disease progression. This article was prepared following a working meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis convened to discuss the value of biochemical markers of matrix metabolism in drug development in osteoarthritis. The best candidates are generally molecules or molecular fragments present in cartilage, bone or synovium and may be specific to one type of joint tissue or common to them all...
March 2014: Postgraduate Medical Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"